Alpa Laboratories growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue−5.9%+4.6%
EBITDA−30.8%−24.2%
Net Income−23.1%+5.9%
EPS (adj.)−23.1%+5.9%
Total Assets+8.8%+13.1%
Total Equity+8.7%+11.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ALPA₹52.20

Alpa Laboratories Limited

· Pharma & Health
₹ CrorePeersBALPHARMAKREBSBIONATCAPSUQVINEETLABNECLIFEAAREYDRUGSBIOFILCHEMMANGALAMMcap ₹110 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue-5.9+4.6
EBITDA-30.8-24.2
Net Income-23.1+5.9
EPS (adj.)-23.1+5.9
Total Assets+8.8+13.1
Total Equity+8.7+11.4
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.